Objectives


The French American Innovation Day is organized yearly in Boston
by the Office of Science and Technology of the French Embassy

This year, the program, chaired by Drs. David Morrow and Ziad Mallat, will provide an in depth discussion of established and emerging biomarkers as effective, non-invasive tools to enhance the detection and management of cardiovascular diseases.  The appropriate contemporary clinical use of available biomarkers will be reviewed, as will the pathophysiological insights, technologic advances, and development strategies guiding biomarker discovery. This program is designed to be of interest to cardiologists, internists, emergency physicians, and researchers.

Educational Objectives

After completing this activity, the participant should be better able to:
  • Identify the pathophysiologic basis for development and application of biomarkers of atherothrombosis and heart failure.
  • Explain the appropriate use of available biomarkers for use in diagnosis, risk assessment and clinical decision-making in patients with ischemic heart disease and with heart failure.
  • Identify pathways and pitfalls for discovery of new biomarkers.
  • Describe novel applications of cardiovascular imaging.
  • Accreditation Statement

    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and the Embassy of France and Inserm. PIM is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation

    Postgraduate Institute for Medicine designates this educational activity for a maximum of 8.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    Disclosure of Conflicts of Interest

    Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), French Embassy, Inserm, Roche Laboratories, Siemens Medical Solutions Diagnostics and Dade Behring, do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, French Embassy, Inserm, Roche Laboratories, Siemens Medical Solutions Diagnostics and Dade Behring. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


    Gold Sponsor

    Silver Sponsors

    Roche
    Siemens
    Dade Behring